News + Filings Transactions
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
|
|
Combs Andrew
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 02/09/2023 |
4
| Combs Andrew (EVP, Head of Chemistry) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Granted 135,000 options to buy
@ $7.2, valued at
$972k
|
|
| 04/04/2022 |
4
| Combs Andrew (EVP, Head of Chemistry) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Exercised 36,062 shares
@ $1.89, valued at
$68.2k
Exercised 36,062 options to buy
@ $1.89, valued at
$68.2k
|
|
| 02/17/2022 |
4
| Combs Andrew (EVP, Head of Chemistry) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Granted 100,000 options to buy
@ $10.58, valued at
$1.1M
|
|
| 12/15/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/22/2021 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 09/29/2020 |
4
| Combs Andrew (EVP, Head of Chemistry) has filed a Form 4 on Prelude Therapeutics Inc|
Txns:
| Bought 1,000 shares
@ $19, valued at
$19k
|
|
| 09/24/2020 |
3
| Combs Andrew (EVP, Head of Chemistry) has filed a Form 3 on Prelude Therapeutics Inc |
|
|